

2740-3994

THIRD EDITION

FUNDAMENTALS OF

# Clinical Trials

**Lawrence M. Friedman**

National Heart, Lung, and Blood Institute,  
National Institutes of Health

**Curt D. Furberg**

Department of Public Health Sciences,  
Bowman Gray School of Medicine

**David L. DeMets**

Biostatistics Department,  
University of Wisconsin

 **Mosby**

St. Louis Baltimore Boston Carlsbad Chicago Naples New York Philadelphia Portland  
London Madrid Mexico City Singapore Sydney Tokyo Toronto Wiesbaden

# Contents

<b>1</b>	<b>Introduction to Clinical Trials</b>	<b>1</b>
	Fundamental Point	2
	What is a Clinical Trial?	2
	Clinical Trial Phases	3
	Phase I Studies	3
	Phase II Studies	4
	Phase III/IV Trials	5
	Why are Clinical Trials Needed?	6
	Problems in the Timing of a Trial	7
	Ethics of Clinical Trials	8
	Study Protocol	10
	References	12
<b>2</b>	<b>What Is the Question?</b>	<b>16</b>
	Fundamental Point	16
	Selection of the Questions	16
	Primary Question	16
	Secondary Questions	17
	Adverse Effects	18
	Ancillary Questions, Substudies	18
	Natural History	19
	Large, Simple Clinical Trials	19
	Intervention	20
	Response Variables	20
	Surrogate Response Variables	24
	General Comments	27
	References	28
<b>3</b>	<b>Study Population</b>	<b>30</b>
	Fundamental Point	30
	Definition of Study Population	30
	Generalization	37

Recruitment	39
References	39
<b>4 Basic Study Design</b>	<b>41</b>
Fundamental Point	42
Randomized Control Studies	43
Nonrandomized Concurrent Control Studies	46
Historical Controls/Data Bases	47
Cross-over Designs	51
Withdrawal Studies	52
Factorial Design	53
Group Allocation Designs	55
Hybrid Designs	55
Studies of Equivalency	55
Large Simple Clinical Trials	56
References	57
<b>5 The Randomization Process</b>	<b>61</b>
Fundamental Point	61
Fixed Allocation Randomization	62
Simple Randomization	63
Blocked Randomization	64
Stratified Randomization	66
Adaptive Randomization Procedures	69
Baseline Adaptive Randomization Procedures	69
Response Adaptive Randomization	72
Mechanics of Randomization	74
Recommendations	75
Appendix	76
Adaptive Randomization Algorithm	76
References	78
<b>6 Blindness</b>	<b>82</b>
Fundamental Point	82
Type of Trials	82
Unblinded Trials	82
Single-Blind Trials	83

Double-Blind Trials	85
Triple-Blind Trials	86
Special Problems in Double-Blind Studies	86
Matching of Drugs	87
Coding of Drugs	89
Unbinding Trials	90
Assessment of Blindness	91
References	92
<b>7 Sample Size</b>	<b>94</b>
Fundamental Point	94
Statistical Concepts	95
Dichotomous Response Variables	100
Two Independent Samples	100
Example	101
Sample Size Tables for Independent Samples	102
Power for Independent Samples	104
Confidence Interval Approach for Independent Samples	105
Paired Dichotomous Response	106
Example	106
Adjusting Sample Size to Compensate for Nonadherence	107
Example	108
Sample Size Calculations for Continuous Response Variables	109
Two Independent Samples	109
Paired Data	110
Example	111
Adjustment for Nonadherence	112
Sample Size for Repeated Measures	112
Example	113
Sample Size Calculations for “Time to Failure”	114
Sample Size for Testing “Equivalency” of Interventions	118
Sample Size for Cluster Randomization	119
Continuous Response	120
Example	120
Binomial Response	121
Example	121
Estimating Sample Size Parameters	122
Multiple Response Variables	123
References	125

<b>8</b>	<b>Baseline Assessment</b>	<b>130</b>
	Fundamental Point	130
	Uses of Baseline Data	130
	Analysis of Baseline Comparability	131
	Stratification and Subgrouping	131
	Evaluation of Change	132
	Natural History Analysis	132
	What is a True Baseline Measurement?	133
	Balance and Imbalance	137
	References	139
<b>9</b>	<b>Recruitment of Study Participants</b>	<b>140</b>
	Fundamental Point	141
	Planning	141
	Strategies and Sources	143
	Conduct	145
	Monitoring	147
	Problems	149
	Solutions	151
	Reasons for Participation	153
	References	153
<b>10</b>	<b>Data Collection and Quality Control</b>	<b>156</b>
	Fundamental Point	157
	Problems in Data Collection	157
	Major Types of Problems	157
	Specific Examples of Variability	158
	Minimizing Poor Quality Data	160
	Design of Protocol and Manual	160
	Development of Forms	160
	Training	161
	Pretesting	162
	Techniques to Reduce Variability	162
	Data Entry	163
	Quality Monitoring	163
	Monitoring of Forms	164
	Monitoring of Procedures	164
	Monitoring of Drug Handling	165

Audits	167
References	167
<b>11 Assessing and Reporting Adverse Effects</b>	<b>170</b>
Fundamental Point	170
Determinants of Adverse Effects	171
Definitions	172
Ascertainment	172
Frequency of Events	174
Length of Follow-up	175
Individual Susceptibility	177
Analysis of Nonadherent Participants	177
Reporting Adverse Effects	178
Other Issues	180
Conclusions	182
References	183
<b>12 Assessment of Health-Related Quality of Life</b>	<b>185</b>
Michelle J. Naughton and Sally A. Shumaker	
Fundamental Point	186
Definitions	186
Primary HRQL Dimensions	187
Additional HRQL Dimensions	188
Uses of HRQL	189
HRQL Indices as Outcome Variables	190
HRQL as Baseline Covariates	191
Methodological Issues	192
Trial Design	192
Study Population	192
Intervention	193
Selection of HRQL Instruments	194
Modes of Administration	195
Frequency of Assessment (acute vs. chronic)	196
Symptom Expression (episodic vs. constant)	197
Functional Impact (present vs. absent)	197
Interpretation	198
Scoring of HRQL Measures	198
Determining the Significance of HRQL Measures	199

Utility Measures and Preference Scaling	199
References	201
<b>13 Participant Adherence</b>	<b>204</b>
Fundamental Point	205
Considerations Before Participant Enrollment	205
Maintaining Good Participant Adherence	210
Adherence Monitoring	213
Special Populations	219
References	220
<b>14 Survival Analysis</b>	<b>223</b>
Fundamental Point	223
Estimation of the Survival Curve	224
Kaplan-Meier Estimate	225
Cutler-Ederer Estimate	232
Comparison of Two Survival Curves	233
Point-by-Point Comparison	233
Comparison of Median Survival Times	234
Total Curve Comparison	234
Example	236
Generalizations	239
Covariate Adjusted Analysis	241
References	243
<b>15 Monitoring Response Variables</b>	<b>246</b>
Fundamental Point	246
Data Monitoring Committee	247
Repeated Testing for Significance	250
Decision for Early Termination	253
Decision to Extend a Trial	259
Statistical Methods Used in Monitoring	261
Classical Sequential Methods	261
Group Sequential Methods	263
Flexible Group Sequential Procedures—Alpha-Spending Functions	266
Applications of Group Sequential Boundaries	269
Asymmetric Boundaries	272

Curtailed Sampling Procedures	272
Other Approaches	275
References	275
<b>16 Issues in Data Analysis</b>	<b>284</b>
Fundamental Point	284
Which Participants Should be Analyzed?	284
Ineligibility	285
Nonadherence	289
Poor Quality or Missing Data	293
Competing Events	296
Covariate Adjustment	297
Surrogates as a Covariate	299
Baseline Variables as Covariates	301
Subgroup Analyses	304
Not Counting Some Events	306
Comparison of Multiple Variables	307
Use of Cutpoints	308
Meta-Analysis of Multiple Studies	308
Rationale and Issues	310
Statistical Methods	313
Appendix	316
Mantel-Haenszel Statistic	316
References	317
<b>17 Closeout</b>	<b>323</b>
Fundamental Point	323
Termination Procedures	323
Poststudy Follow-up	326
Data Clean-up and Verification	328
Storage of Study Material	329
Dissemination of Results	330
References	331
<b>18 Reporting and Interpreting of Results</b>	<b>333</b>
Fundamental Point	334
Guidelines for Reporting	334
Interpretation	335



Publication Bias	336
Did the Trial Work as Planned?	337
How Do the Findings Compare with Results from Other Studies?	340
What Are the Clinical Implications of the Findings?	341
References	342
<b>19 Multicenter Trials</b>	<b>345</b>
Fundamental Point	345
Reasons for Multicenter Trials	345
Conduct of Multicenter Trials	347
Data Monitoring Committee	349
Steering Committee	350
Assembly of Investigators	350
General Comments	354
References	355
Index	357